DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Hidalgo-Tenorio, Carmen
  • dc.contributor.author Vinuesa, David
  • dc.contributor.author Plata, Antonio
  • dc.contributor.author Martín Dávila, Pilar
  • dc.contributor.author Iftimie, Simona Mihaela
  • dc.contributor.author Sequera, Sergio
  • dc.contributor.author Loeches, Belén
  • dc.contributor.author Lopez-Cortés, Luis Eduardo
  • dc.contributor.author Fariñas, Mari Carmen
  • dc.contributor.author Fernández-Roldan, Concepción
  • dc.contributor.author Javier-Martinez, Rosario
  • dc.contributor.author Muñoz-Millán, Patricia
  • dc.contributor.author Arenas-Miras, María Del Mar
  • dc.contributor.author Martínez-Marcos, Francisco Javier
  • dc.contributor.author Miró, José María
  • dc.contributor.author Herrero, Carmen
  • dc.contributor.author Bereciartua, Elena
  • dc.contributor.author de Jesús, Samantha E.
  • dc.contributor.author Pasquau, Juan
  • dc.date.accessioned 2021-02-26T08:04:33Z
  • dc.date.available 2021-02-26T08:04:33Z
  • dc.date.issued 2019
  • dc.description.abstract Objectives: To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. Methods: A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. Results: Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20€) and 557 days for IE (283,187.45€). Conclusions: DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Dávila P, Iftimie S, Sequera S, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019 Oct 19; 18(1): 30. DOI: 10.1186/s12941-019-0329-6
  • dc.identifier.doi http://dx.doi.org/10.1186/s12941-019-0329-6
  • dc.identifier.issn 1476-0711
  • dc.identifier.uri http://hdl.handle.net/10230/46599
  • dc.language.iso eng
  • dc.publisher BioMed Central
  • dc.rights Copyright © The Author(s) 2019. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by/4.0/
  • dc.subject.keyword Bloodstream infection
  • dc.subject.keyword Dalbavancin
  • dc.subject.keyword Endocarditis
  • dc.title DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)